Table 2.
Adverse event | EB patients (n = 75) | Median time to bevacizumab discontinuation (months) |
---|---|---|
Any event | 32 (42.7) | 8.2 |
Proteinuria | 12 (16.0) | – |
Epistaxis | 3 (4.0) | – |
Hypertension | 2 (2.7) | – |
Hemorrhoidal hemorrhage | 2 (2.7) | – |
Data are presented as n (%)
EB erlotinib plus bevacizumab